Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Marino

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
The AAPS Journal|December 17, 2008
P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate?Praveen V Balimane, Anthony Marino, Saeho Chong
Journal of Surgical Case Reports|June 21, 2014
Post-radiotherapy vesicocutaneous fistula presenting as gas/fluid-filled groin swellingJonathan Yin, Anthony Marino, Peter Cooke, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|June 23, 2004
Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discoveryPraveen V Balimane, Karishma Patel, Anthony Marino, et al.
Journal of Biomolecular Screening|January 30, 2007
Use of cryopreserved transiently transfected cells in high-throughput pregnane X receptor transactivation assayZhengrong Zhu, Jaime Puglisi, David Connors, et al.
Biopharmaceutics & Drug Disposition|September 6, 2005
Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokineticsZheng Yang, Lisa Zadjura, Celia D'Arienzo, et al.
Pharmaceutical Research|July 31, 2023
Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug InteractionsJessica Chu, Erika Panfen, Linna Wang, et al.
Journal of Biomolecular Screening|September 25, 2013
Development of novel, 384-well high-throughput assay panels for human drug transporters: drug interaction and safety assessment in support of discovery researchHuaping Tang, Ding Ren Shen, Yong-Hae Han, et al.
Bioorganic & Medicinal Chemistry Letters|July 15, 2009
Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivoNy Sin, Brian L Venables, Keith D Combrink, et al.
Journal of Medicinal Chemistry|December 28, 2002
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonistNatesan Murugesan, Zhengxiang Gu, Steven Spergel, et al.
Bioorganic & Medicinal Chemistry Letters|December 16, 2006
Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailabilityKuo-Long Yu, Ny Sin, Rita L Civiello, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
The AAPS Journal|December 17, 2008
P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate?Praveen V Balimane, Anthony Marino, Saeho Chong
Journal of Surgical Case Reports|June 21, 2014
Post-radiotherapy vesicocutaneous fistula presenting as gas/fluid-filled groin swellingJonathan Yin, Anthony Marino, Peter Cooke, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|June 23, 2004
Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discoveryPraveen V Balimane, Karishma Patel, Anthony Marino, et al.
Journal of Biomolecular Screening|January 30, 2007
Use of cryopreserved transiently transfected cells in high-throughput pregnane X receptor transactivation assayZhengrong Zhu, Jaime Puglisi, David Connors, et al.
Biopharmaceutics & Drug Disposition|September 6, 2005
Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokineticsZheng Yang, Lisa Zadjura, Celia D'Arienzo, et al.
Pharmaceutical Research|July 31, 2023
Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug InteractionsJessica Chu, Erika Panfen, Linna Wang, et al.
Journal of Biomolecular Screening|September 25, 2013
Development of novel, 384-well high-throughput assay panels for human drug transporters: drug interaction and safety assessment in support of discovery researchHuaping Tang, Ding Ren Shen, Yong-Hae Han, et al.
Bioorganic & Medicinal Chemistry Letters|July 15, 2009
Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivoNy Sin, Brian L Venables, Keith D Combrink, et al.
Journal of Medicinal Chemistry|December 28, 2002
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonistNatesan Murugesan, Zhengxiang Gu, Steven Spergel, et al.
Bioorganic & Medicinal Chemistry Letters|December 16, 2006
Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailabilityKuo-Long Yu, Ny Sin, Rita L Civiello, et al.
Pageof 2